Navidea to appeal potential delisting from NYSE American Exchange

Navidea Biopharmaceuticals announced it is intending to appeal potential delisting from the NYSE American Exchange. “Although the traditional exchange has been a part of Navidea’s history and may be in the future, our strategy and approach remains resolute in the face of change. The company’s progress is clear, and the impact of the changes we have made will continue to move us forward. Navidea will continue to focus on using our Fix, Fund Propel approach, our strategic vision to advance Navidea’s innovative technology to market, and the delivery of value to our stockholders,” said Josh Wilson, Director.